ABSTRACT

Background and Aim: The coronavirus disease 2019 (COVID-19) outbreak has rapidly crossed international boundaries and placed increasing demands on healthcare facilities worldwide. Patients with diabetes and uncontrolled blood glucose levels are at increased risk for poor clinical outcomes and in-hospital mortality related to COVID-19. Therefore, achieving good glycaemic control is of paramount importance among hospitalised patients with COVID-19. Basal-bolus insulin therapy is a safe and effective intervention for the management of hyperglycaemia in hospitalised patients. The aim of this article is to provide a practical guidance for the use of the basal-bolus insulin regimen in hospitalised patients with COVID-19 and diabetes mellitus.

Methods: This guidance document was formulated based on the review of available literature and the combined personal experiences of the authors. We provide a comprehensive review on the use of the basal-bolus insulin regimen, including its principles, rationale, indications, prerequisites, initiation, and dose titration, and also suggest targets for blood glucose control and different levels of capillary blood glucose monitoring. Various case scenarios are used to illustrate how optimal glucose control can be achieved, such as through adjustments in doses of prandial and basal insulin, the use of correctional insulin dosing and changes in the timing and content of major and minor meals.

Conclusion: The practical guidance for the use of the basal-bolus insulin regimen in hospitalised patients with COVID-19 and diabetes mellitus presented here can be used for patients admitted to hospital for indications other than COVID-19 and for those in ambulatory care.

Keywords: Basal-bolus insulin; Basal insulin; Continuous glucose monitoring system; Correctional insulin; COVID-19; Diabetes; Hyperglycaemia; In-hospital hyperglycaemia; Prandial insulin
Uncontrolled hyperglycaemia is associated with poor clinical outcomes among hospitalised patients with coronavirus disease 2019 (COVID-19).

This review provides a practical guidance on the use of the basal-bolus insulin regimen for management of hyperglycaemia in hospitalised patients.

Various case scenarios are provided to illustrate how to achieve optimal blood glucose control through adjustments in doses of prandial and basal insulin, the use of correctional insulin dosing and changes in timing and content of major and minor meals.

This guidance can be used for patients admitted for indications other than COVID-19 and for those in ambulatory care.

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has affected 213 countries worldwide, with more than 5.4 million confirmed cases and more than 340,000 deaths at the time of writing this paper [1]. The outbreak of this disease has resulted in an unparalleled increase in admissions to dedicated COVID-19 facilities, with diabetes, hypertension and cardiovascular disease reported to be major comorbidities among patients with COVID-19 [2]. The pooled prevalence of diabetes in a meta-analysis of nine observational studies of patients hospitalised with COVID-19 was reported to be 9% (95% confidence interval 6–12%) [3]. A high insulin requirement has been reported for the management of hyperglycaemia in patients with COVID-19, especially in those with severe disease, which has been attributed to a combination of severe insulin resistance and decreased insulin secretion due to beta-cell dysfunction [4]. Among patients with COVID-19, diabetes is associated with an increased severity of infection, rapid disease progression, poor clinical outcomes and mortality [5], but this association is mainly driven by the severity of hyperglycaemia. In a retrospective study of > 7000 patients with COVID-19 and pre-existing type 2 diabetes mellitus (T2DM), the in-hospital mortality rate was tenfold lower (1.1 vs. 11%) in patients with well-controlled blood glucose levels (upper limit ≤ 10 mmol/L or 180 mg/dl) than in those with poor blood glucose control (upper limit > 10 mmol/L or 180 mg/dl) during the course of hospitalisation [6]. Thus, it is of paramount importance that hospitalised patients with COVID-19 achieve good glycaemic control.

Intensive insulin regimens, such as basal-bolus insulin therapy and continuous intravenous insulin infusion, are known to be safe and effective therapies for the management of hospitalised patients with hyperglycaemia [7–9]. However, given the rising burden of patients requiring hospital admission for COVID-19 and a possible deployment of healthcare personnel without required expertise in the management of hyperglycaemia in these patients, the implementation of an effective insulin therapy may be challenging. Here, we discuss a practical and simplified approach for the management of hyperglycaemia in hospitalised patients using the basal-bolus insulin regimen. This practical guidance is formulated based upon the available evidence and the combined clinical experiences of the authors, with the aim to help clinicians better manage the patients under their care.

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
BASIC PRINCIPLES OF THE BASAL-BOLUS INSULIN REGIMEN

Rationale Basal-bolus insulin regimen implies the use of one or two doses of intermediate- or long-acting (basal) insulin and three, or rarely, four doses of short-acting (bolus or prandial) insulin. The basal insulin regulates the rise in blood glucose due to endogenous glucose production through the processes of glycogenolysis and gluconeogenesis, and the bolus insulin prevents the meal-related rise in blood glucose levels.

Pharmacokinetics of Different Insulin Preparations Basal insulin can be classified into: (1) conventional preparations, such as neutral protamine hagedorn (NPH) insulin, which is intermediate acting (duration of action 12–16 h), and (2) insulin analogues, such as insulin detemir, insulin glargine and insulin degludec, which are intermediate or long acting (duration of action 12 to > 24 h) (Table 1). Similarly, bolus insulin can be classified into: (1) conventional preparations, such as regular insulin, which are short acting (onset and duration of action 30–60 min and 6–8 h, respectively); (2) rapid-acting insulin analogs, such as insulin lispro, insulin aspart and insulin glulisine (onset and duration of action 5–15 min and 3–5 h, respectively) (Table 1); and (3) ultra-rapid-acting insulin analogues, such as fast-acting insulin aspart (onset of action is twofold faster than that of insulin aspart) [10–13]. Thus, while regular insulin provides coverage during the post-absorptive period (beyond 4 h following a major meal), implying some degree of basal glucose regulation, the action of rapid-acting insulin is mainly limited

Table 1 Pharmacokinetic properties of human insulin and insulin analogues following subcutaneous injection

| Insulin preparation | Onset of action | Peak of action (h) | Duration of action (h) | Time of administration |
|---------------------|----------------|-------------------|-----------------------|------------------------|
| Prandial insulin    |                |                   |                       |                        |
| Regular             | 30–60 min      | 2–4               | 6–8                   | 30 min before a meal   |
| Lispro              | 10–15 min      | 1–1.5             | 3–5                   | 5–15 min before a meal |
| Aspart              | 10–15 min      | 1–2               | 3–5                   | 5–15 min before a meal |
| Glulisine           | 10–15 min      | 1–2               | 3–5                   | 5–15 min before a meal |
| Fast-acting insulin aspart | 3–5 min | 1 | 3–4 | At the start of a meal or up to 20 min after starting a meal |
| Basal insulin       |                |                   |                       |                        |
| NPH                 | 2.5–3 h        | 5–7               | 12–16                 | Bedtime. When given twice daily, morning dose is administered at around 9 a.m. |
| Detemir             | 2–3 h          | 6–8               | 12–24                 | Bedtime. May be required twice daily |
| Glargine U-100      | 2–3 h          | No peak           | ≈ 24                  | Given once a day at a fixed time, generally bedtime. May be required twice daily on rare occasions |
| Glargine U-300      | 4–6 h          | No peak           | > 24 (≈ 36)           | Given once a day at a fixed time |
| Degludec            | 1–4 h          | No peak           | > 24 (≈ 42)           | Given once a day at a fixed time |

Values in table have been published earlier [10–12]
*Glargine U-100, U-300 Insulin glargine solution 100 units/ml, 300 units/ml, NPH Neutral protamine hagedorn*
to the postprandial period (up to 4 h following a major meal).

**INDICATIONS FOR THE BASAL-BOLUS INSULIN REGIMEN**

The basal-bolus insulin regimen should be considered in the following scenarios (Electronic Supplementary Material [ESM] Table 1):

1. Suboptimal blood glucose control with oral glucose-lowering drugs and/or basal insulin and/or premixed insulin.
2. Use of oral glucose-lowering drugs is not safe due to underlying organ dysfunction.
3. Initiation or escalation of oral glucose-lowering drugs is likely to cause delay in achieving normoglycaemia and adversely affect clinical outcomes.
4. Transition from intravenous insulin infusion to a subcutaneous insulin regimen.
5. Patient was already using this regimen prior to hospital admission.

**PREREQUISITES FOR BASAL-BOLUS INSULIN REGIMEN**

The following factors should be kept in mind before initiating a basal-bolus insulin regimen (ESM Table 1):

1. The patient should receive enteral nutrition per oral administration or via a feeding tube. The latter may be relevant for a patient emerging from or currently on ventilatory support. A regular diet plan should be followed, with a fixed number of calories and a fixed carbohydrate proportion for each major and minor meal (or major and minor feed). In the hospital setting, especially in the current COVID-19 scenario, very little support is likely to be available to assess the adequacy of teaching programmes aimed at educating the patient on carbohydrate counting; therefore, a meal with a fixed carbohydrate proportion should be the preferred option.

2. The patient should consume three major and three minor meals (or feeds) or three major and four minor meals (or feeds) (the latter option is preferred if the interval between lunch and dinner [or the second and third major feed] is large).

3. There should be a gap of at least 2 h between a major meal (or feed) and minor meal (or feed). This gap ensures that the release of prandial insulin is appropriate to match the post-meal rise in blood glucose and that there is no second unregulated wave of glucose release during this period.

4. Meal (or feed) timings (both major and minor) should be relatively fixed.

**BLOOD GLUCOSE TARGETS**

Glycaemic targets for the management of hospitalised patients with hyperglycaemia are based upon capillary blood glucose monitoring. Although blood glucose meters use capillary whole blood for the measurement of glucose, most devices currently used report a plasma equivalent value (to facilitate comparison with the laboratory value) [14]. It should be noted that capillary and venous plasma glucose values better approximate in the fasting state than the postprandial state, with capillary values in the latter state possibly being higher by 20–25% [15].

Glycaemic targets for hospitalised patients with COVID-19 should be decided based on age, comorbidities and presence or absence of diabetes-related complications. For individuals who are young, have no comorbidities or diabetes-related complications and tight blood glucose control can be achieved without causing undue hypoglycaemia, fasting blood glucose (FBG) of ≤ 120 mg/dl (6.7 mmol/L) and 2-h postprandial blood glucose (PPBG) of ≤ 160 mg/dl (8.9 mmol/L) should be targeted. For older individuals or those with comorbidities and diabetes-related complications for whom the risk of hypoglycaemia is higher, blood glucose targets should be relaxed to FBG ≤ 140 mg/dl (7.8 mmol/L) and PPBG ≤ 180 mg/dl (10 mmol/L). The upper
HOW TO DECIDE UPON THE INSULIN DOSE WHEN STARTING THE BASAL-BOLUS INSULIN REGIMEN?

Patients who were already on a basal-bolus insulin regimen prior to admission and have good blood glucose control can be continued on the same doses of insulin. Further adjustments can be made based on capillary blood glucose monitoring as detailed in the following sections of this review. For patients who are insulin naïve, insulin therapy can be initiated at an empirical total daily dose (TDD) of 0.4 units/kg/day [8]. The TDD should be reduced to 0.2 units/kg/day in elderly patients (> 65 years) and in those with renal dysfunction, liver disease, cardiac disease, autonomic neuropathy or hypoglycaemia unawareness due to the heightened risk of hypoglycaemia and its associated complications in this patient subgroup.

In the scenario in which regular insulin is used for prandial coverage, the calculated TDD is divided equally into four portions, with the implication of one portion for the basal insulin injection and one portion each for the three prandial insulin injections (25% of TDD in each insulin injection). However, when an insulin analogue is used for prandial coverage, the TDD should be divided into 50% for basal insulin and 50% for prandial insulin (further divided into three equal portions for each meal) [8].

Transition from intravenous insulin infusion to the subcutaneous basal-bolus insulin regimen should ideally occur when the patient is consuming meals regularly, blood glucose levels are controlled and stable and any underlying illness has improved significantly. Typically, the TDD is calculated as 80% of the total daily insulin requirement on intravenous infusion in the last 24–48 h [9]. The 20% decrement is accounted for by increased ambulation, improvement in glucotoxicity and decreased stress-related hyperglycaemia when patient is switched to a subcutaneous insulin regimen. The TDD can be proportionately divided into basal and prandial components as described above. However, when a marked difference in insulin requirement is evident across the different time segments (breakfast to lunch, lunch to dinner, dinner to midnight and midnight to before breakfast), the insulin dose for each segment should be calculated separately (ESM Table 2).

BLOOD GLUCOSE MONITORING

Important Factors to Consider in Patients with COVID-19 Admitted to Hospital

Pre-analytical factors, such as blood pH, hypoxia, hypotension and extreme hematocrit concentrations, can affect the performance of capillary blood glucose monitoring and should be given due consideration in the current scenario [16]. While most blood glucose meter test strips use the glucose oxidase method, which is specific for glucose, it is worth mentioning that the glucose dehydrogenase-pyruroloquinoline (GDH-PQQ) method is not glucose.

| Patient characteristics | Target blood glucose |
|-------------------------|----------------------|
| Fasting blood glucose | 2-h postprandial blood glucose |
| Young, no comorbidities or diabetes-related complications | ≤ 120 mg/dl | ≤ 160 mg/dl (6.7 mmol/L) |
| Patients with terminal illness and/or limited life expectancy or at high risk of hypoglycaemia | ≤ 140 mg/dl | ≤ 180 mg/dl (7.8 mmol/L) |

* Could be further relaxed to 220 mg/dl (12.2 mmol/L) if the target value cannot be achieved without causing undue hypoglycaemia.
specific. Consequently, GDH-PQQ can react with other sugars, such as maltose, galactose and xylose, resulting in false high blood glucose readings in the presence of these molecules [17]. Maltose is product of icodextrin metabolism (used in peritoneal dialysis solutions) and also a constituent of intravenous immunoglobulin, which is an experimental therapy for patients with severe COVID-19 pneumonia [18]. Erro-
neously high blood glucose readings leading to fatal insulin dose calculation errors may occur in such scenarios when using a GDH-PQQ-based glucometer [17, 19–21]. For this reason, GDH-
PQQ-based blood glucose meters are not rec-
ommended for use in the hospital setting by the US Food and Drug Administration [22].

Pattern of Blood Glucose Monitoring

A mix of preprandial and postprandial blood glucose values should be monitored along with the blood glucose values at 3 a.m., when needed. Paired values around a meal are more informative for prandial insulin adjustments, as discussed subsequently in following sections. Since intensive blood glucose control is needed in patients with active infection, the monitoring frequency should be higher, especially when blood glucose levels are out of the target range. The frequency of monitoring can be reduced once blood glucose levels are stable and in the target range. We suggest the following three levels of monitoring.

**Level 1 Monitoring**  Level 1 monitoring consists of making one paired measurement (pre- and 2-h post-meal) each day. The meal around which the paired measurement is performed should be rotated on a daily basis (e.g. breakfast on day 1, lunch on day 2, dinner on day 3 and so on). This strategy should be used when >75% of the values are in target range without any episode of hypoglycaemia (Table 3).

**Level 2 Monitoring**  Level 2 monitoring consists of making two paired measurements each day. As in level 1 monitoring, the meals around which the paired measurements are performed should be rotated on a daily basis (e.g. breakfast and lunch on day 1, lunch and dinner on day 2, dinner and breakfast on day 3 and so on). In a scenario where values around a specific meal are predominantly affected (e.g. lunch), one pair may be fixed for that meal and other rotated on a daily basis between other two meals (e.g. breakfast and dinner). This strategy should be used when 50–75% blood glucose values are in the target range (Table 4).

**Level 3 Monitoring**  Level 3 monitoring consists of performing blood glucose tests before all meals (pre-breakfast, pre-lunch and pre-dinner) and after all meals (2-h post-breakfast, post-lunch and post-dinner) on each day (6-point monitoring). This strategy should be used when <50% of the blood glucose values are in the target range. Blood glucose testing at 3 a.m. is required in a scenario where fasting blood glucose values are in target range without any episode of hypoglycaemia (Table 3).

### Table 3 Proposed strategy for level 1 monitoring of capillary blood glucose

| Day  | BBF | ABF | BL | AL | BDN | ADN | 3 a.m. | Remarks |
|------|-----|-----|----|----|-----|-----|--------|---------|
| Day 1 | x   |     | x  |    |     |     |        |         |
| Day 2 |     | x   |     | x  |     |     |        |         |
| Day 3 | x   |     |     |    | x   |     |        |         |
| Day 4 |     |     | x  |    |     |     |        |         |

Level 1 capillary blood glucose monitoring is advised when >75% blood glucose values are in the target range and there is no episode of hypoglycaemia.

ABF After breakfast, ADN after dinner, AL after lunch, BBF before breakfast, BDN before dinner, BL before lunch

* Blood glucose should be monitored at 3 a.m. when the fasting blood glucose level is persistently out of the target range.
glucose is persistently elevated, as discussed in following sections (Table 5).

**Table 4 Proposed strategy for level 2 monitoring of capillary blood glucose**

| Day   | BBF | ABF | BL | AL | BDN | ADN | 3 a.m.| Remarks |
|-------|-----|-----|----|----|-----|-----|-------|---------|
| Day 1 | x   | x   | x  | x  | x   |     |       |         |
| Day 2 |     | x   | x  | x  |     |     | x     |         |
| Day 3 | x   | x   |    |    | x   |     | x     |         |
| Day 4 | x   |     | x  | x  | x   |     | x     |         |

Level 2 capillary blood glucose monitoring is advised when 50–75% of blood glucose values are in the target range

In case values around a specific meal are predominantly affected (e.g., lunch), one pair may be fixed for that meal and other rotated on daily basis between the other two meals (e.g., breakfast and dinner)

**Table 5 Proposed strategy for level 3 monitoring of capillary blood glucose**

| Day   | BBF | ABF | BL | AL | BDN | ADN | 3 a.m.| Remarks |
|-------|-----|-----|----|----|-----|-----|-------|---------|
| Day 1 | x   | x   | x  | x  | x   |     |       |         |
| Day 2 |     | x   | x  | x  |     |     | x     |         |
| Day 3 | x   | x   |    |    | x   |     | x     |         |
| Day 4 | x   |     | x  | x  | x   |     | x     |         |

Level 3 capillary blood glucose monitoring is advised when < 50% of the blood glucose values are in the target range

Blood glucose should be monitored at 3 a.m. when the fasting blood glucose is persistently out of the target range

Role of Continuous Glucose Monitoring System

A continuous glucose monitoring system (CGMS) device measures the glucose level in the interstitial fluid instead of the blood. The components of a CGMS device are: (1) a sensor, which is inserted subcutaneously into the patient’s abdomen or forearm; (2) a transmitter, which is attached to the sensor; and (3) a receiver which displays and stores glucose data. The sensor reports the interstitial glucose level every 5–15 min and can be worn for a duration of 6–14 days (varies according to the type of sensor). Unlike conventional monitoring, which provides snapshots of blood glucose values, CGMS provides information on glucose trends and fluctuations [23, 24]. CGMS devices can be: (1) real-time or unmasked (e.g., Guardian Connect [Medtronic], G5 Mobile [Dexcom], G6 [Dexcom], FreeStyle Libre Flash [Abbott Diabetes Care]) and (2) retrospective or masked (e.g., iPro2 [Medtronic], FreeStyle Libre Pro Flash [Abbott Diabetes Care]) [25]. While the former devices allow real-time assessment of glucose levels (at a site remote from the patient), in the latter devices, data can only be reviewed retrospectively after the device has been worn for a certain period of time. Thus, a real-time CGMS not only provides an opportunity for stringent glucose monitoring but also reduces the need for repeated contact between the healthcare worker and the patient, which is very relevant in the current COVID-19 scenario. Since a lag time of 7–15 min exists between interstitial fluid glucose level and blood glucose level, the sensor value may be less accurate when glucose values are changing rapidly, such
as after a meal and during or before a hypo-
glycaemic episode.

**INSULIN DOSE TITRATION**

Once insulin therapy has been initiated, the
doses of prandial and basal insulin will need
titration based on blood glucose monitoring.
The titration of insulin dose is based on two
main principles: (1) having an understanding of
the segment of the day when insulin works; (2)
having an understanding of the type of adjust-
ment needed.

**Understanding the Segment of the Day**

**When Insulin Works**

Each insulin dose in the basal-bolus regimen
works during a particular segment of the day. Prandial insulin administered before breakfast
predominantly acts from breakfast to lunch
(around 8 a.m. to 1 p.m.); prandial insulin given
before lunch predominant acts from lunch to
dinner (around 1 p.m. to 7–8 p.m.); prandial
insulin given before dinner predominantly acts
from dinner to midnight (8 p.m. to 12 a.m.); and basal insulin given at bedtime (especially
NPH) predominantly acts from midnight to
breakfast (12 a.m. to 8 a.m.). Although there
may be some overlap in action, this broad
concept helps the clinician to determine the
appropriate dose adjustment based upon the
demarcation of the segment(s) during which
blood glucose targets are not achieved.

**Understanding the Type of Adjustment**

**Needed**

There are four main types of adjustments that
can be made to achieve optimal blood glucose
control; these are: (1) prandial insulin adjust-
ments; (2) correctional insulin adjustments, (3)
basal insulin adjustments; and (4) meals and
snacks adjustments. These are described in
detail in the following sections.

---

**Prandial Insulin Adjustments**

The postprandial rise in blood glucose is physi-
ological and to a certain degree desirable. An
idea of the degree of postprandial elevation that
can be considered to be normal can be derived
from an individual’s glycaemic targets. For
example, if the optimal preprandial target for an
individual is ≤ 120 mg/dl (6.7 mmol/L) and the
optimal postprandial target is ≤ 160 mg/dl
(8.9 mmol/L), the difference between the two,
that is, 40 mg/dl (2.2 mmol/L), can be taken as
the upper limit of the allowed postprandial
excursion. If the difference is consistently
> 40 mg/dl (2.2 mmol/L), and the postprandial
glucose is also out of range (> 160 mg/dl or
8.9 mmol/L) on two or more consecutive occa-
sions for a given meal, this difference needs to
be addressed. The healthcare professional
should ensure that the insulin injection tech-
nique is correct, that there is an adequate time
gap between the injection of prandial insulin
and the meal (30 min for regular insulin) and
that the quality and quantity of carbohydrate in
the meal is appropriate and relatively fixed. In a
scenario where these issues are not relevant to
the problem or postprandial excursion persists
despite these issues being addressed, the dose of
prandial insulin should be increased to reduce
the postprandial excursion to < 40 mg/dl
(2.2 mmol/L). If the postprandial excursion
is < 40 mg/dl (2.2 mmol/L), but the postpran-
dial value is out of the target range due to a high
preprandial value (> 120 mg/dl or 6.7 mmol/L),
measures to control preprandial blood glucose
should be adopted (discussed later in review).

It is also important to understand that the
postprandial blood glucose value should not be
lower than the preprandial blood glucose value
as this situation increases the chances of hypo-
glycaemia. In such a scenario, if the meal intake
was adequate and there were no other factors
which could explain the fall in blood glucose
(such as exercise, vomiting or diarrhea), the
dose of prandial insulin should be reduced. A
dose reduction should be strongly considered if
postprandial blood glucose is < 100 to 120 mg/
dl (5.6–6.7 mmol/L) or hypoglycaemia occurs in
the postprandial period. As a general strategy, if
postprandial blood glucose is less than
preprandial blood glucose by ≤ 20 mg/dl
Table 6  Examples of prandial insulin adjustments for a 45-year-old man (body weight 64 kg) receiving a total daily insulin dose of 40 units

| Case scenario | BG (mg/dl) | Interpretation | Problem areas | Suggested actions |
|---------------|-----------|----------------|---------------|------------------|
| **Scenario 1** |           |                |               |                  |
|               | 105 (BBF) | 1. ABF not in target range<br>2. ABF–BBF > 40 mg/dl | 1. Quantity and quality of carbohydrate in breakfast<br>2. Insulin injection technique<br>3. BBF insulin dose<br>4. Insulin–meal gap | 1. Review quantity and quality of carbohydrate in breakfast<br>2. Educate patient on proper insulin injection technique<br>3. Increase BBF dose of regular insulin<br>4. Ensure 30-min gap between regular insulin and breakfast |
|               | 195 (ABF) |                |               |                  |
|               | 155 (BL)  |                |               |                  |
| **Scenario 2** |           |                |               |                  |
|               | 108 (BDN) | 1. ADN and BBF both not in target range<br>2. ADN–BBF > 40 mg/dl (indicates that dose of basal insulin is adequate) | 1. Quantity and quality of carbohydrate in dinner<br>2. Insulin injection technique<br>3. BDN insulin dose<br>4. Insulin–meal gap | 1. Review quantity and quality of carbohydrate in dinner<br>2. Educate patient on proper insulin injection technique<br>3. Increase BDN dose of regular insulin<br>4. Ensure 30-min gap between regular insulin and dinner |
|               | 220 (ADN) |                |               |                  |
|               | 160 (BBF) |                |               |                  |
| **Scenario 3** |           |                |               |                  |
|               | 105 (BDN) | 1. ADN < BBN and ADN < 100 mg/dl | 1. Quantity and quality of carbohydrate in dinner<br>2. Insulin injection site/other factors<br>3. BDN insulin dose<br>4. Insulin–meal gap | 1. Review quantity and quality of carbohydrate in dinner<br>2. Enquire whether BDN insulin was administered on thigh or if patient did some brisk walking or vomited or had diarrhea after dinner<br>3. Decrease BDN dose of regular insulin<br>4. Ensure that the gap between insulin and meal was not too long (> 30 min) |
|               | 95 (ADN)* |                |               |                  |
|               | –         |                |               |                  |

For conversion from mg/dl to mmol/L, divide the value in mg/dl by 18

*BG Blood glucose

* On that night, patient should remain vigilant for hypoglycaemia (especially around 12–1 a.m.) and consume extra snacks or decrease basal insulin dose.
(1.1 mmol/L), then prandial insulin should be decreased by 1 unit (by 10% if the dose of prandial insulin is > 10 units); if the difference exceeds 20 mg/dl (1.1 mmol/L), prandial insulin should be decreased by 2 units (by 20% if the dose of prandial insulin is > 10 units). Prandial insulin adjustment is explained in the context of various case scenarios in Table 6.

**Correctional Insulin Adjustment**

When the elevation in preprandial blood glucose is very remarkable (> 200 to 250 mg/dl or 11.1 to 13.9 mmol/L), the treating physician may need to administer an additional correctional dose of short-acting insulin in addition to the usual prandial dose [26]. This correctional dose is given with the aim to rapidly reduce the elevated blood glucose levels, and the dose is determined based on a correction factor. The correction factor indicates the decrease in blood glucose (mg/dl) expected with 1 unit of short-acting insulin and depends upon the insulin sensitivity of the person being treated. As a rule, the higher the TDD (units/kg body weight), the lower the insulin sensitivity and correction factor. Correction factors based on TDD are shown in Table 7.

**Table 7** Correction factor for the use of correctional insulin in patients with uncontrolled preprandial blood glucose

| Total daily dose (units/kg/day) | Correction factor (mg/dl)\(^a\) |
|-------------------------------|---------------------------------|
| < 0.5                         | 50                              |
| 0.5 to < 1                    | 40                              |
| 1 to < 1.5                    | 30                              |
| 1.5–2                         | 20                              |
| > 2                           | Consider intravenous insulin infusion instead of correctional insulin for uncontrolled hyperglycaemia |

For conversion from mg/dl to mmol/L, divide the value in mg/dl by 18

\(^a\) Correction factor indicates the decrease in blood glucose (mg/dl) expected with 1 unit of short-acting insulin

The practical use of a correctional dose of insulin can be better explained with an example, as follows. A 46-year-old man with T2DM for 3 years, a body weight of 72 kg and no comorbidities or diabetes-related complications is being treated with a basal-bolus insulin regimen. His TDD of insulin is 45 units (0.63 unit/kg body weight), injected as 10 units of regular insulin before each meal and 15 units of insulin glargine at bedtime. His correction factor (Table 7) is 40, that is, 1 unit of regular insulin is expected to decrease the blood glucose level by 40 mg/dl (2.2 mmol/L). In a scenario in which his before-lunch blood glucose is 280 mg/dl (higher than the target blood glucose of 120 mg/dl [6.7 mmol/L] by 80 mg/dl [4.4 mmol/L]), he needs 80/40, that is, 2 units of correctional insulin. Thus, in addition to the 10 units of regular insulin for prandial coverage, he should receive an additional 2 units of regular insulin (total dose being 14 units of regular insulin).

Since insulin sensitivity is dynamic and varies depending on multiple factors, such as time of the day (higher at night), severity of underlying illness and use of concomitant drugs, the correction factor should be adjusted based on the changes in blood glucose observed with correctional insulin doses over the previous 2–3 days.

**Basal Insulin Adjustments**

Adjustments in bedtime basal insulin may be done based upon the fasting or pre-breakfast blood glucose value. The ideal decrease in blood glucose expected with basal insulin is determined by the difference in the upper limit of targets for post-dinner (160 mg/dl or 8.9 mmol/L) and pre-breakfast blood glucose (120 mg/dl or 6.7 mmol/L) values. Therefore, the action of basal insulin can be considered to be optimal if the decline in blood glucose is around 40 mg/dl (2.2 mmol/L). In case the fasting or pre-breakfast blood glucose is above target despite a decline of ≥ 40 mg/dl (2.2 mmol/L), the elevated post-dinner blood glucose value may need to be addressed with the principles delineated above.

If the fasting or pre-breakfast blood glucose is out of the target range and the overnight
| Case scenario | BG (mg/dl) | Interpretation | Problem areas | Suggested actions |
|---------------|------------|----------------|---------------|------------------|
| **Scenario 1** | 154 (ADN) 60 (3 A.M.) 155 (BBF) | 1. BBF not in target range | 1. Missed or inadequate bedtime snack | 1. Missed or inadequate bedtime snack 2. Dose of basal insulin | 1. Ensure adequate bedtime snack 2. Decrease dose of basal insulin |
| **Scenario 2** | 158 (ADN) 140 (3 a.m.) 164 (BBF) | 1. BBF not in target range 2. 3 a.m. > 100 mg/dl | 1. Quantity and quality of carbohydrate in bedtime snack | 1. Check quantity and quality of carbohydrate in bedtime snack 2. Insulin technique 3. Dose of basal insulin | 1. Check quantity and quality of carbohydrate in bedtime snack 2. Educate patient on proper insulin injection technique 3. Increase dose of basal insulin |
| **Scenario 3** | 142 (ADN) 94 (3 a.m.) 80 (BBF) | 1. BBF 70–90 mg/dl 2. 3 a.m. < 100 mg/dl | 1. Inadequate bedtime snack 2. Dose of basal insulin | 1. Ensure adequate bedtime snack | 1. Ensure adequate bedtime snack 2. Decrease dose of basal insulin |
| **Scenario 4** | 114 (BBF) 142 (AL) 212 (BDN) | 1. BDN not in target range 2. AL in target range | 1. Quantity and quality of carbohydrate in evening snack | 1. Review quantity and quality of carbohydrate in evening snack |
|              |            |                | 2. Dose of morning basal insulin | 1. Review quantity and quality of carbohydrate in evening snack |

For conversion from mg/dl to mmol/L, divide the value in mg/dl by 18

* Patient being treated with twice daily basal insulin (bedtime and morning 9 am)

* In refractory cases, addition of short- or rapid-acting insulin before evening snack may be warranted
Table 9: Examples of meal and snack adjustments for a 45-year-old man (body weight 64 kg) receiving a total daily insulin dose of 40 units

| Case scenario | BG (mg/dl) | Interpretation | Problem area(s) | Suggested action(s) |
|---------------|------------|----------------|-----------------|---------------------|
| Scenario 1    | 105 (BBF)  | 1. BL not in target range  
               | 135 (ABF)  | 2. ABF-BBF < 40 mg/dl  
               | 175 (BL)   | 3. ABF in target range  |
|               |            | 1. Mid-morning snack | 1. Review quantity and quality of carbohydrate in mid-morning snack |
| Scenario 2    | 105 (BBF)  | 1. ABF and BL both not in target range  
               | 168 (ABF)  | 2. ABF-BBF > 40 mg/dl  
               | 205 (BL)   | 3. BL > ABF  |
|               |            | 1. Quantity and quality of carbohydrate in breakfast | 1. Review quantity and quality of carbohydrate in breakfast  
               |            | 2. Insulin injection technique  
               |            | 3. Insulin dose before breakfast  
               |            | 4. Insulin–meal gap  
               |            | 5. Quantity and quality of carbohydrate in mid-morning snack(s)  |
|               |            | 1. Review quantity and quality of carbohydrate in breakfast  
               |            | 2. Educate patient on proper insulin injection technique  
               |            | 3. Increase BBF dose of regular insulin  
               |            | 4. Ensure 30-min gap between regular insulin and meal  
               |            | 5. Review quantity and quality of carbohydrate in mid-morning snack  |
| Scenario 3    | 105 (BBF)  | 1. BBF and ABF in target range  
               | 120 (ABF)  | 2. BL < BBF  
               | 78(BL)*    | 3. Other factors  |
|               |            | 1. Delayed lunch timings | 1. Ensure lunch is not delayed  
               |            | 2. Missed or inadequate mid-morning snack(s)  
               |            | 3. Enquire whether if patient did some brisk walking or vomited or had diarrhea around lunch time |

For conversion from mg/dl to mmol/L, divide the value in mg/dl by 18

* Patient reported hypoglycaemic symptoms around lunch time
decline is $< 40 \text{ mg/dl} \ (2.2 \text{ mmol/L})$, the dose of basal insulin may be increased. However, before increasing the dose, the treating physician should be certain that that inadequate decline is not reflective of a faulty insulin injection technique, the Somogyi phenomenon (midnight hypoglycaemia causing fasting hyperglycaemia) or extra snacking during this interval (between 12 and 8 a.m.).

Blood glucose should be checked at 3 a.m. if two or more consecutive fasting or pre-breakfast blood glucose values are above the target. A 3 a.m. blood glucose value of $< 70 \text{ mg/dl} \ (3.9 \text{ mmol/L})$ suggests that late night hypoglycaemia is the possible cause of the raised morning blood glucose level. This situation will require a decrease in the dose of basal insulin and/or the addition of or increase in bedtime snacks. If the 3 a.m. blood glucose blood is $\geq 100 \text{ mg/dl} \ (5.6 \text{ mmol/L})$, the dose of basal insulin should be increased after excluding early morning tea or snacks and a faulty insulin injection technique.

If the fasting or pre-breakfast blood glucose is 70–90 mg/dl (3.9–5.0 mmol/L), the dose of basal insulin should be decreased by 1 unit (10% if the dose of basal insulin is $> 10$ units). If the fasting or pre-breakfast blood glucose is $< 70 \text{ mg/dl} \ (3.9 \text{ mmol/L})$ or the patient experiences nocturnal hypoglycaemia, the basal insulin dose should be decreased by 2 units (10–20% if the dose of basal insulin is $> 10$ units) and the bedtime snack(s) policy reviewed.

In a scenario where twice-daily basal insulin is used, the adjustments may be more complex. It should be understood that the primary action of basal insulin is that of regulating pre-meal blood glucose values. Accordingly, the morning dose of basal insulin should be adjusted based upon the pre-dinner blood glucose value and less commonly the pre-lunch blood glucose value. The increase in the dose of morning basal insulin is only justified if the upward drift of blood glucose starts after the peak of lunch time prandial insulin is over, implying that the post-lunch blood glucose is in target but the pre-dinner and evening blood glucose values are elevated. However, when both the pre-dinner blood glucose and post-lunch blood glucose levels are elevated, it is the dose of prandial (before lunch) insulin that should primarily be adjusted, and not that of basal insulin. Similarly, in the case of preprandial hypoglycaemia (during the pre-lunch or pre-dinner period), the morning basal insulin dose should be decreased, provided the hypoglycaemia is not explained by missed or inadequate snacks or other factors (such as exercise, vomiting and/or diarrhea). Basal insulin adjustment is explained in the context of various case scenarios in Table 8.

**Adjustment of Meals and Snacks**

Medical nutrition therapy (MNT) is the cornerstone of effective blood glucose management in patients with diabetes [27, 28]. The broad aim of MNT is to provide an individual with adequate calories to meet his/her nutrition demands. Total calories are split in three major meals (breakfast, lunch and dinner; or major feed 1, major feed 2 and major feed 3) and three to four minor meals (snacks) or feeds (mid-day [10–11 a.m.], early evening [4–5 p.m.], late evening [6–7 p.m.] and bedtime [10–11 p.m.]) to provide nutrition throughout the day, regulate the rise in blood glucose after a meal and avoid hypoglycaemia. A fixed meal pattern in terms of timing and content is desirable in the hospital setting (as discussed above). However, even with relatively fixed diet patterns, individual adjustments may be needed.

In a scenario in which post-prandial blood glucose is in target, but the subsequent preprandial value is elevated (for instance, pre-breakfast blood glucose of 115 mg/dl (6.4 mmol/L), post-breakfast blood glucose of 145 mg/dl (8.1 mmol/L) and pre-lunch blood glucose of 140 mg/dl (7.8 mmol/L), the carbohydrate quality (glycaemic index) and quantity (calories) of the intervening snack (mid-morning snack in this case) should be checked. Similarly, if the post-prandial blood glucose is within normal range, but the subsequent preprandial value is low ($< 80 \text{ mg/dl} \ or 4.4 \text{ mmol/L}$) or patient experiences hypoglycaemic symptoms at this time [for instance, pre-breakfast blood glucose of 100 mg/dl (5.6 mmol/L), post-breakfast blood glucose of 120 mg/dl (6.7 mmol/L) and pre-lunch blood glucose of 72 mg/dl (4.0 mmol/L)], it should be checked if
the intervening snack (mid-morning snack in this case) was missed or was inadequate in terms of calories. Meals and snacks adjustment has been explained with various case scenarios in Table 9.

Discrepancies in patient’s diet pattern can result in glycaemic variability. Therefore, the patient (or attending healthcare provider) should be advised to note diet content, meal timings and any variance from the previous days in the remarks column of the blood glucose log or in a separate diary for review by the treating physician.

SPECIAL SITUATIONS

Type 1 Diabetes Mellitus and Diabetic ketoacidosis One study reported that a large number of patients with COVID-19 developed diabetic ketoacidosis (DKA), hyperosmolar hyperglycaemic state (HHS) or a combination of both [29]. It has also been found that COVID-19 may mask the symptoms of DKA [30]. In a study of 64 patients with type 1 diabetes mellitus (T1DM) who tested positive for COVID-19 or COVID-19-like disease, a significant proportion had hyperglycaemia ($n = 32, 50\%$) or DKA ($n = 19, 30\%$) [31]. These results strongly suggest that all patients with COVID-19 should be screened for hyperglycaemia and that blood or urine ketone testing should be considered in patients with a blood glucose value $> 250$ mg/dl (13.9 mmol/L) [32, 33].

For patients with T1DM who are already on a basal-bolus insulin regimen, the same regimen can be continued, with dose titration performed according to the results of blood glucose monitoring. However, in cases where ketosis or ketoacidosis is present, intravenous insulin infusion should be the initial preferred strategy. On the other hand, in the current scenario of COVID-19, switching patients on continuous subcutaneous insulin infusion or insulin pump to the basal-bolus insulin regimen should be strongly considered—unless expert guidance is available to manage the former.

Use of Glucocorticoids Selected patients with moderate to severe COVID-19 may require glucocorticoids, usually administered as intravenous methylprednisolone 0.5–1.0 mg/kg/day in two divided doses [34]. The use of glucocorticoids may worsen hyperglycaemia and necessitate adjustments in insulin therapy. A detailed discussion of the management of glucocorticoid-induced hyperglycaemia is beyond the scope of this article and the reader is directed to excellent reviews on this topic [35–37].

Acute Kidney Injury Acute kidney injury (AKI) has been reported as a complication of severe COVID-19. In a multi-hospital study involving > 5400 patients admitted with COVID-19, AKI developed in 36.6% patients, of whom 14.3% required dialysis [38]. The development of renal dysfunction is associated with a reduced clearance of insulin and hence necessitates a reduction in the dose of exogenous insulin to prevent hypoglycaemia [39]. In addition, the requirement of insulin may vary on pre- and post-dialysis days. Initiation of dialysis is associated with an improvement in peripheral insulin resistance and hence the dose requirement may decrease further following dialysis [40, 41].

Concomitant Use of Oral Agents with Potential Effect on Blood Glucose Patients with COVID-19 may receive oral hydroxychloroquine (HCQ), which is also an effective anti-hyperglycaemic agent [42]. In such cases, the patient should be kept under close watch for hypoglycaemia, and an adjustment in insulin dose should be considered. The use of oral dipeptidyl peptidase-4 (DPP-4) inhibitors has also been reported to be a safe and effective treatment in patients with mild to moderate hyperglycaemia and in stable clinical condition, and a reduction of insulin dose may be needed in situations where these agents are co-administered with insulin [43]. The use or continuation of glucose-lowering oral drugs other than DPP-4 inhibitors is generally not recommended for acutely ill patients with COVID-19 due to the potential for abrupt deterioration in clinical status [44]. The risk for euglycaemic DKA and volume depletion contraindicates the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in any hospitalised patient at this time [44].
Use of this Practical Guidance in Other Scenarios and for Ambulatory Patients

We have presented a practical guidance for the management of patients on basal-bolus insulin therapy. This guidance can also be used for patients hospitalised for indications other than COVID-19. Some patients are primarily admitted for glycaemic control and are often encouraged to perform some physical activity (such as walking) in the hospital premises, when possible. In such a scenario, one should ensure that the timing and quantum of physical activity is relatively fixed. Preferably, physical activity should be avoided late in evening or after dinner to prevent nocturnal hypoglycaemia. Additionally, brisk walking after an insulin injection in the thigh should be avoided as it can result in rapid absorption of insulin and subsequent hypoglycaemia [45]. A close watch for hypoglycaemia should be maintained in every hospitalised patient receiving insulin therapy. During the course of the hospital stay, the patient should be educated on recognising the symptoms of hypoglycaemia, as well as on its acute management and prevention of future episodes. In ambulatory patients, the adjustments in insulin doses should not be too frequent and should be done preferably after the patient’s blood glucose log has been reviewed for at least 3–4 days. The patient should be educated on principles of insulin dose self-adjustment highlighted in the previous section. The unsupervised use of correctional insulin could be risky and should be avoided.

Strengths and Limitations of this Practical Guidance Document

The proposed guidance is based on a review of available literature and the combined extensive clinical experiences of the authors. It provides a comprehensive review on the use of the basal-bolus insulin regimen in routine clinical practice with the help of different case scenarios. The principles and concepts highlighted can be easily understood by healthcare personnel with lesser training and experience than skilled physicians in the management of hyperglycaemia in hospitalised patients. The guidance may be used for settings beyond COVID-19 and for ambulatory patient care. A limitation of this practical approach is that it has not been tested in a formal manner.

CONCLUSION

This review provides a practical guidance on the use of the basal-bolus insulin regimen in patients with diabetes mellitus hospitalised with COVID-19. We have used various case scenarios to illustrate adjustments in doses of prandial and basal insulin, the use of correctional insulin and changes in timing and content of major and minor meals for achieving optimal blood glucose control. This guidance can be used in the future for patients admitted for indications other than COVID-19 and for those in ambulatory care.

ACKNOWLEDGEMENTS

Funding. No funding or sponsorship was received for this study or publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author contributions. The concept for this paper was conceived by AG, YG and NT. The first draft was prepared by BA and AG, which was read and edited by YG and NT. All authors approved the final version of this manuscript.

Disclosures. Bhawna Attri, Alpesh Goyal; Yashdeep Gupta and Nikhil Tandon have nothing to disclose.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any studies with human
participants or animals performed by any of the authors.

Data Availability. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. WHO Coronavirus Disease (COVID-19) Dashboard. https://www.covid19.who.int/?gclid=EAIaIQobChMmla_myfTN6Q1VRWvCh2LygtpEAYAASAEgLyBvD_BwE. Accessed 26 May 2020.

2. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–10.

3. Wang X, Wang S, Sun L, Qin G. Prevalence of diabetes mellitus in 2019 novel coronavirus: A meta-analysis. Diabetes Res Clin Pract. 2020;164:108200. https://doi.org/10.1016/j.diabres.2020.108200.

4. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020; 8(60):P546–50. https://doi.org/10.1016/S2213-8587(20)30152-2.

5. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395-403.

6. Zhu L, She Z, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31:1–10.

7. McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am. 2012;41(1):175–201.

8. Umpierrez G, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.

9. Moghissi ES, Korytkowski MT, Dinardo MM, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31.

10. Donner T. Insulin—pharmacology, therapeutic regimens and principles of intensive insulin therapy. Endotext. https://www.ncbi.nlm.nih.gov/books/NBK278938/.

11. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–83.

12. Borrelli F, Rossetti P, Busciantella Ricci N, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447–522.

13. Heise T, Hövelmann U, Zijlstra E, Stender-Petersen K, Jacobsen JB, Haahr H. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. Drugs Aging. 2017;34(1):29–38.

14. Tonyushkina K, Nichols JH. Glucose meters: a review of technical challenges to obtaining accurate results. J Diabetes Sci Technol. 2009;3(4):971–80.

15. Kotwal N, Pandit A. Variability of capillary blood glucose monitoring measured on home glucose monitoring devices. Indian J Endocrinol Metab. 2012;16:S248–S251251.

16. Klonoff DC. Point-of-care blood glucose meter accuracy in the hospital setting. Diabetes Spectr. 2014;27(3):174–9.
17. Frias JP, Lim CG, Ellison JM, et al. Review of adverse events associated with false glucose readings measured by GDH-PQQ-based glucose test strips in the presence of interfering sugars. Diabetes Care. 2010;33:728–9. https://doi.org/10.2337/dc09-1822.

18. Xie Y, Cao S, Dong H, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;S0163-4453(20)30172-9. https://doi.org/10.1016/j.jinf.2020.03.044.

19. Tsai CY, Lee SC, Hung CC, et al. False elevation of blood glucose levels measured by GDH-PQQ-based glucometers occurs during all daily dwells in peritoneal dialysis patients using icodextrin. Perit Dial Int. 2010;30:329–35.

20. Disse E, Thivolet C. Related hypoglycemic coma in a diabetic patient on peritoneal dialysis due to interference of icodextrin metabolites with capillary blood glucose measurements. Diabetes Care. 2004;27:2279. https://doi.org/10.2337/diacare.27.9.2279.

21. Chakraborty PP, Patra S, Bhattacharjee R, Chowdhury S. Erroneously elevated glucose values due to maltose interference in mutant glucose dehydrogenase pyrroloquinolinequinone (mutant GDH-PQQ) based glucometer. BMJ Case Rep. 2017;2017:bcr2017219928. https://doi.org/10.1136/bcr-2017-219928.

22. US Food and Drug Administration. FDA perspective. Public health notification: potentially fatal errors with GDH-PQQ glucose monitoring technology. https://www.diabetestecnology.org/FDA/Harper%2520PQQ%2520and%2520other%2520interference.pdf. Accessed 26 May 2020.

23. Ajjan R, Slattery D, Wright E. Continuous glucose monitoring: a brief review for primary care practitioners. Adv Ther 2019;36(3):579–96.

24. Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41:2265–74.

25. Funtanilla VD, Candidate P, Caliendo T, Hilas O. Continuous glucose monitoring: a review of available systems. P T. 2019;44(9):550–3.

26. Nau KC, Lorenzetti RC, Cucuzzella M, Devine T, Kline J. Glycemic control in hospitalized patients not in intensive care: beyond sliding-scale insulin. Am Fam Physician. 2010;81:1130–5.

27. American Diabetes Association. Lifestyle management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S46–S60.

28. Viswanathan V, Krishnan D, Kalra S, et al. Insights on medical nutrition therapy for type 2 diabetes mellitus: an Indian perspective. Adv Ther. 2019;36:520–47.

29. Rayman G, Lumb A, Kennon B, et al. Guidance on the management of diabetic ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabet Med. 2020. https://doi.org/10.1111/dme.14328.

30. Potier L, Julla JB, Roussel R, et al. COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes. DiabetesMetab. 2020;S1262–3636(20)30081–1. https://doi.org/10.1016/j.diabet.2020.05.004.

31. Ebekozien OA, Noor N, Gallagher MP, Alonso GT. Type 1 Diabetes and COVID-19: preliminary findings from a multicenter surveillance study in the U. S. Diabetes Care. 2020;dc201088. https://doi.org/10.2337/dc20-1088.

32. Goyal A, Gupta S, Gupta Y, Tandon N. Proposed guidelines for screening of hyperglycemia in patients hospitalized with COVID-19 in low resource settings. Diabetes Metab Syndr. 2020;14(5):753–56. https://doi.org/10.1016/j.dsx.2020.05.039.

33. Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud. 2016;13:217–25.

34. Fadel R, Morrison AR, Vahia A, et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Clin Infect Dis. 2020;ciaa601. https://doi.org/10.1093/cid/ciaa601.

35. Radhakutty A, Burt MG. Management of endocrine disease: Critical review of the evidence underlying management of glucocorticoid-induced hyperglycemia. Eur J Endocrinol. 2018;179:R207–R218. https://doi.org/10.1530/EJE-18-0315.

36. Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother. 2018;52(1):86–90.

37. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutierrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6:1073–81.

38. Hirsch JS, Ng JH, Ross DW. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209–18. https://doi.org/10.1016/j.kint.2020.05.006.

39. Iyengar R, Franzese J, Gianchandani R. Inpatient glycemic management in the setting of renal
insufficiency/failure/dialysis. Curr Diabetes Rep. 2018;18:75.

40. Sudha MJ, Salam HS, Viveka S, Udupa AL. Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. J Nat Sci Biol Med. 2017;8:64–8.

41. Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27:135–45.

42. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14:241–6.

43. Koufakis T, Mustafa OG, Zebekakis P, Kotsa K. Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close Diabetes Med. 2020. https://doi.org/10.1111/dme.14329.

44. Korytkowski M, Antinori-Lent K, Drincic A, Hirsch IB, McDonnell ME, Rushakoff R, et al. A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic. J Clin Endocrinol Metab. 2020. https://doi.org/10.1210/clinem/dgaa342.

45. Tandon N, Kalra S, Balhara YP, et al. Forum for injection technique and therapy expert recommendations, India: the Indian recommendations for best practice in insulin injection technique, 2017. Indian J Endocrinol Metab. 2017;21:600.